Beyond Barriers, Big Crystallization Hurdles: Atropisomerism in Beyond Rule of Five Compounds Explored by Computational and NMR Studies
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Nikolaos Angelos Stamos und 6 weiteren Autor:innen. Beteiligte Einrichtung: CMC, DDS, Discovery Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Stereochemical purity, stability, and selection of a suitable solid-state form are pivotal factors in pharmaceutical development, particularly for complex beyond Rule of 5 (bRo5) compounds. In this study, we explore the intricate interplay between atropisomerism and crystallization using two model bRo5 compounds, namely, ACBI1 and BI201335, both violating three of four Lipinski's rules. One of the tool compounds exhibits Class 2 atropisomeric behavior, and the other is devoid of it. A diverse array of crystallization methods, including solution-phase crystallization, cocrystallization, and salt formation, were applied, revealing the critical role of atropisomerism-induced stereochemistry in polymorphism and nucleation outcomes. In silico torsion profile calculations and NMR studies were employed to elucidate the rotational energy barriers and confirm the presence or absence of atropisomerism. This comprehensive analysis highlights the significance of understanding stereochemical phenomena such as atropisomerism in designing and developing bRo5 compounds. By integrating advanced analytical techniques and crystallization strategies, this work provides novel insights into tailoring pharmaceutical properties for next-generation therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CMC, DDS, Discovery Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
- Computational Chemistry, Medicinal Chemistry, Discovery Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
- Analytical Development, Development, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
- Open Innovation, Medicinal Chemistry, Discovery Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
- ELDICO Scientific AG, 4123 Allschwil, Switzerland.
ORCID-Profile: Nikolaos Angelos Stamos, Florian Montel
Förderung
- Boehringer Ingelheim
Zitieren
APA
Stamos, N. A., Ries, B., Schneider, R., Tzvetkova, P., Montel, F., Jandl, C., & Werthmann, U. (2025). Beyond Barriers, Big Crystallization Hurdles: Atropisomerism in Beyond Rule of Five Compounds Explored by Computational and NMR Studies. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00204
Vancouver
Stamos NA, Ries B, Schneider R, Tzvetkova P, Montel F, Jandl C, et al. Beyond Barriers, Big Crystallization Hurdles: Atropisomerism in Beyond Rule of Five Compounds Explored by Computational and NMR Studies. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00204
BibTeX
@article{Stamos2025,
author = {Stamos, Nikolaos Angelos and Ries, Benjamin and Schneider, Regina and Tzvetkova, Pavleta and Montel, Florian and Jandl, Christian and Werthmann, Ulrike},
title = {Beyond Barriers, Big Crystallization Hurdles: Atropisomerism in Beyond Rule of Five Compounds Explored by Computational and NMR Studies},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00204}
}
EUVIMED